FDA warning letter closeout: how to check whether issues were corrected

01

A warning letter starts a public compliance record

FDA warning letters communicate the agency's position that it observed significant violations and generally request a response within a stated period. The recipient can describe corrective actions or disagree and provide supporting information. FDA evaluates what follows.

The response deadline is not a resolution date. A firm's response may contain plans that have not yet been implemented, and FDA may request more information or conduct a follow-up inspection. The public page may not include every exchange.

FDA cautions that later interactions may change the regulatory status of issues described in a warning letter. Responsible provider research therefore uses the original letter as a dated record, not a permanent present-tense verdict.

02

What FDA requires before issuing a closeout

FDA's closeout program applies to warning letters issued on or after September 1, 2009. The agency says it may issue a closeout after evaluating corrective actions and determining that the cited violations were addressed.

The Regulatory Procedures Manual states that promises are not enough. Corrections must actually be made and verified. The usual standard is a follow-up inspection, although FDA can rely on other verified, appropriate, and reliable information when an inspection is not needed.

The agency also checks that follow-up information does not reveal other significant violations. A closeout is therefore stronger evidence than a company's announcement that it responded, but it remains limited to FDA's evaluation of that case.

03

Why a letter may have no closeout

FDA's manual identifies several reasons. A violation may be uncorrectable. The recipient may be verified as out of business. A firm may stop the cited operation while continuing other business, and FDA may decide not to close the letter solely on that representation.

Internet cases create a special verification problem because website claims can be removed and restored. FDA says it may not issue a closeout based only on website correction and will consider whether the available evidence demonstrates sustained compliance.

A missing closeout can also mean review or follow-up is incomplete or that public information is limited. It is accurate to say no closeout was posted as of the access date. It is not automatically accurate to say FDA rejected the response, the violation continues, or the company ignored the letter.

04

What a closeout does not mean

A closeout does not convert a compounded drug into an FDA-approved drug or make a pharmacy FDA-approved. It does not certify clinical quality, endorse marketing claims, or decide whether a treatment is appropriate for a person.

FDA says future inspections and regulatory activity can test whether corrections remain adequate and sustainable. New violations can lead to action without further notice. A closeout should not be displayed as a permanent clean bill of health.

The original warning letter also remains part of the historical record. Fair reporting presents the original findings and the closeout together, with dates, so readers can see both the concern and verified correction.

05

A step-by-step status search

Search FDA's warning-letter database using the exact recipient name and letter reference number. Open the record rather than relying on a search snippet. Record the issue date, issuing office, products or practices, website-review or inspection dates, and response deadline.

Check the response and closeout columns and links. If a closeout is posted, read its scope and date. If not, search the firm's name for later FDA inspection classifications, recalls, import alerts, injunctions, seizures, consent decrees, and new warning letters. Then check current state license records for the relevant pharmacy or clinician.

Company names and ownership can change. Match addresses, facility identifiers, and former names. If the evidence does not connect the records confidently, do not merge them. Contact the issuing FDA office or use FOIA when a material question cannot be resolved from public sources.

• →Recipient and reference number
• →Original issue and inspection dates
• →Exact cited products and claims
• →Posted response
• →Posted closeout and scope
• →Later inspection or enforcement
• →Current state licenses
• →Access date and unresolved gaps

06

Language for provider profiles and news updates

When there is no closeout, write: FDA issued a warning letter on the stated date; no closeout was posted in the database as of the checked date. Avoid open, active, unresolved, or outstanding unless FDA uses that term or another source proves it.

When there is a closeout, write: FDA posted a closeout on the stated date after evaluating corrective actions addressing the cited violations. Add that the closeout does not approve the company or product and does not prevent future action.

Update a profile when a closeout, follow-up inspection, recall, license action, or ownership change appears. Preserve the earlier version and source trail under the corrections policy. Current status deserves equal visibility with the original warning, not a footnote hidden after a damaging headline.